5:39 PM
 | 
Sep 05, 2012
 |  BC Extra  |  Company News

FDA delays crofelemer decision again

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) said FDA delayed a decision for the second time on an NDA for crofelemer to treat diarrhea in HIV/AIDS patients on antiretroviral therapy. Salix now expects...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >